

miR-122 promotes virus-induced lung disease by targeting SOCS1

Adam M. Collison,¹ Leon A. Sokulsky,¹ Elizabeth Kepreotes,¹ Ana Pereira de Siqueira,¹ Matthew Morten,¹ Michael R. Edwards,² Ross P. Walton,² Nathan W. Bartlett,^{2,3} Ming Yang,³ Thi Hiep Nguyen,³ Sebastian L. Johnston,² Paul S. Foster,³ and Joerg Mattes^{1,4}

¹Priority Research Centre GrowUpWell, Experimental and Translational Respiratory Medicine Group, School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia. ²Airway Disease Infection Section, National Heart and Lung Institute, Medical Research Council & Asthma UK Centre in Allergic Mechanisms of Asthma, Imperial College London, London, United Kingdom. ³Priority Research Centre for Healthy Lungs, University of Newcastle and Hunter Medical Research Institute, Newcastle, New South Wales, Australia. ⁴Department of Paediatric Respiratory and Sleep Medicine, John Hunter Children's Hospital, Newcastle, New South Wales, Australia.

Authorship note: AMC and LAS authors contributed equally to this work.

Conflict of interest: SLJ reports personal fees from Virtus Respiratory Research, Myelo Therapeutics GmbH, Concert Pharmaceuticals, Bayer, Synairgen, Novartis, Boehringer Ingelheim, Chiesi, Gerson Lehrman Group, resTORbio, Bioforce, Materia Medical Holdings, PrepBio Pharma, Pulmotect, Virion Health, Lallemand Pharma, and AstraZeneca. In addition, SLJ has the following patents: UK patent application no. GB 0405634.7 (Wark PA, Johnston SL, Holgate ST, Davies DE. Anti-virus therapy for respiratory diseases, March 12 2004; with royalties paid); International patent application no. PCT/GB05/50031 (Wark PA, Johnston SL, Holgate ST, Davies DE. Interferon-beta for anti-virus therapy for respiratory diseases, March 12 2004; with royalties paid); and UK patent application no. 6779645.9 (Davies DE, Wark PA, Holgate ST, Johnston SL. Interferon lambda therapy for the treatment of respiratory disease, granted August 15 2012; licensed).

Copyright: © 2021, Collison et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.

Submitted: February 5, 2019

Accepted: March 2, 2021

Published: April 8, 2021

Reference information: *JCI Insight*. 2021;6(7):e127933.
<https://doi.org/10.1172/jci.insight.127933>.

Virus-induced respiratory tract infections are a major health burden in childhood, and available treatments are supportive rather than disease modifying. Rhinoviruses (RVs), the cause of approximately 80% of common colds, are detected in nearly half of all infants with bronchiolitis and the majority of children with an asthma exacerbation. Bronchiolitis in early life is a strong risk factor for the development of asthma. Here, we found that RV infection induced the expression of miRNA 122 (miR-122) in mouse lungs and in human airway epithelial cells. In vivo inhibition specifically in the lung reduced neutrophilic inflammation and CXCL2 expression, boosted innate IFN responses, and ameliorated airway hyperreactivity in the absence and in the presence of allergic lung inflammation. Inhibition of miR-122 in the lung increased the levels of suppressor of cytokine signaling 1 (SOCS1), which is an in vitro-validated target of miR-122. Importantly, gene silencing of SOCS1 in vivo completely reversed the protective effects of miR-122 inhibition on RV-induced lung disease. Higher miR-122 expression in nasopharyngeal aspirates was associated with a longer time on oxygen therapy and a higher rate of treatment failure in 87 infants hospitalized with moderately severe bronchiolitis. These results suggest that miR-122 promotes RV-induced lung disease via suppression of its target SOCS1 in vivo. Higher miR-122 expression was associated with worse clinical outcomes, highlighting the potential use of anti-miR-122 oligonucleotides, successfully trialed for treatment of hepatitis C, as potential therapeutics for RV-induced bronchiolitis and asthma exacerbations.

Introduction

Virus-induced respiratory tract infections are among the most common causes for hospital admissions during childhood, manifesting as viral bronchiolitis and pneumonia in infants and asthma exacerbations and pneumonia/pneumonitis in older children. Rhinoviruses (RVs), the cause of approximately 80% of common colds, are detected in nearly half of all infants admitted to the hospital with bronchiolitis and in most children with acute asthma and viral pneumonia (1–5). While RV-induced respiratory tract infections are self-limiting in immune-competent adults, the lack of preventative and disease-modifying therapeutic strategies for bronchiolitis in infancy alone results in an increased health burden. In the US alone, costs amount to \$1.73 billion (US dollars) per year.

miRNAs are small, noncoding RNA strands (approximately 22-nucleotides long) that target the 3'-untranslated region of mRNAs to inhibit posttranscriptional gene expression (6). Although miRNAs have hundreds of in silico-predicted targets, very few are validated in vitro or in vivo. Indeed, identifying mRNA targets and demonstrating the in vivo functional relevance of a miRNA-mRNA circuit is critical for understanding the role of these noncoding RNA species in health and complex disease settings. Commonly, this is inferred by showing an inverse correlation between miRNA expression and its mRNA target in vivo. However, it would be far more conclusive to suppress the expression of a miRNA of interest using oligonucleotides or gene depletion in vivo to induce a miRNA-deficient phenotype (7) and then concurrently




Figure 1. Rhinovirus-induced lung disease and miR-122 expression in infant mice. Rhinovirus (RV) replication could be detected in the lower airways at 24 hours after inoculation (A) ($n = 3-6$ mice per group). RV infection induced inflammation in bronchoalveolar lavage fluid (BALF) (B) ($n = 3-6$ mice per group) and the expression of the murine IL-8 analogs CXCL1 and CXCL2 (C and D) ($n = 4-8$ mice per group) as well as IFN- β and IFN- λ (E and F) ($n = 4-8$ mice per group). A TaqMan miRNA qPCR array, including 750 miRNAs from MIRBase v21, identified 4 miRNAs significantly upregulated in the airways of mice 24 hours after infection with RV when compared with UV controls normalized to the small nuclear-RNA (sn-RNA) control gene RNU6b (G) ($n = 6$ mice per group). miR-122 was induced by RV in immortalized human airways basal cells in submerged culture (H) ($n = 3$ independent cultures). * $P < 0.05$, calculated using 1-way ANOVA with multiple comparisons correcting the false discovery rate 2-stage step-up method of Benjamini, Krieger, and Yekutieli for all panels, except for G, where moderated 2-tailed t test and Westfall-Young correction for multiple testing was used. SAL, saline vehicle; UV-RV, UV-inactivated RV. Data are shown as the mean \pm SEM.

silencing or blocking the proposed mRNA target of that miRNA to reverse the in vivo phenotype. miRNAs are well known to regulate inflammatory, antimicrobial, and antiviral immune responses in vivo (8–11). Furthermore, RV infection has been associated with differentially expressed miRNA found in extracellular vesicles of upper airway secretions from young children (12). Inflammatory signaling through NF- κ B underpins the immune response to RV, and infants with bronchiolitis and RV infection have a distinct nasal airway miRNA profile associated with the upregulation of NF- κ B (12). We and others have previously shown a critical role of NF- κ B activation in promoting experimental RV-induced lung disease (13–15). However, the role of miRNAs in the pathogenesis of this common infection remains elusive.

Results

To gain insights into the role of miRNA in the pathogenesis of RV-induced lung disease such as bronchiolitis, we inoculated 7-day-old infant mice with RV or UV-inactivated RV as a control via the nasal route. This resulted in detectable RV replication in the lower airways, influx of inflammatory cells into the bronchoalveolar space, upregulated expression of the neutrophil chemoattractants CXCL1 and CXCL2 in the lung, and the production of innate antiviral IFN production (Figure 1, A–F). Next, we determined miRNA expression in lung tissues using a PCR-based miRNA array and identified miRNA 122 (miR-122) as the most significantly upregulated miRNA in the lungs of infant mice 24 hours after RV inoculation (Figure 1G). miR-122 was also overexpressed in human airway epithelial cells 24 hours after RV exposure in vitro (Figure 1H). To therapeutically modulate miR-122 expression in the lungs via the airway route, we infected mice with RV and suppressed miR-122 expression levels (Figure 2A) by employing miR-122 antagonists, which are chemically modified oligonucleotides exactly complementary to the single-stranded miR-122 that has been associated with an RNA-silencing complex. Targeting miR-122 with antagonists




Figure 2. Effect of miR-122 inhibition on rhinovirus-induced lung disease in adult mice. Naive adult mice infected with RV had reduced miR-122 expression in their airways 24 hours after RV infection when treated with miR-122 antagonist (A.122/RV) as compared with mice treated with a scrambled control antagonist (SCR/RV) (A) ($n = 4-5$ mice per group). Mice treated with A.122/RV had reduced neutrophil influx into the BALF (B) ($n = 6-8$ mice per group) and fewer myeloperoxidase-positive cells (neutrophils) in the lung tissue (C) ($n = 6-8$ mice per group) when compared with mice treated with SCR/RV. Representative images of myeloperoxidase-positive neutrophils are shown (D) ($n = 6-8$ mice per group) (original magnification, $\times 400$). Expression of mouse IL-8 analogs CXCL1 and CXCL2 was upregulated following RV infection, and CXCL2 was reduced by A.122 treatment (E and F) ($n = 6-8$ mice per group). Mice treated with miR-122 antagonist were protected from RV-induced AHR (G) ($n = 6-8$ mice per group). Expression of RV was increased in airways of infected mice at 24 hours and more pronounced with the inhibition of miR-122 but returned to baseline by 96 hours in all groups (H) ($n = 6-8$ mice per group). IFN- β and IFN- λ were increased in the airways of infected mice and more pronounced when miR-122 was inhibited (I and J). ($n = 6-8$ mice per group). * $P < 0.05$, calculated using 1-way ANOVA with multiple comparisons correcting the false discovery rate 2-stage step-up method of Benjamini, Krieger, and Yekutieli, except for A and G, where 2-tailed t test and 2-way ANOVA were used, respectively. UVRV, UV-inactivated RV. Data are shown as the mean \pm SEM.




Figure 3. Effect of miR-122 inhibition on rhinovirus-induced exacerbation of allergic lung disease in adult mice. House dust mite (HDM) sensitized and challenged mice infected with RV had increased expression of miR-122 in the airways (SCR/RV/HDM), which was ameliorated by antagomir treatment targeting miR-122 (A122/RV/HDM) (A) ($n = 4-6$ mice per group). Increased RV replication was observed in the airways in mice where miR-122 was inhibited (B) ($n = 4-6$ mice per group). Mice treated with miR-122 antagomir were protected from RV-induced AHR (C) ($n = 4-6$ mice per group) and had reduced neutrophil influx (D) into the BALF when compared with mice treated with a scrambled control antagomir (SCR/RV/HDM) ($n = 3-4$ mice per group). Expression of IFN- β and IFN- λ in the airways was further increased by inhibition of miR-122 (A122/RV/HDM) (E and F) ($n = 4-6$ mice per group). CXCL1 and CXCL2 were also increased by RV and reduced by inhibition of miR-122 (G and H) ($n = 4-6$ mice per group). * $P < 0.05$, calculated using 1-way ANOVA with multiple comparisons correcting the false discovery rate 2-stage step-up method of Benjamini, Krieger, and Yekutieli, except for A and C, where 2-tailed t test and 2-way ANOVA were used, respectively. UVRV, UV-inactivated RV. Data are shown as the mean \pm SEM.

in vivo resulted in reduced influx of inflammatory cells into the bronchoalveolar space (Figure 2B) and less neutrophilic inflammation in lung tissue as compared with treatment with scrambled nonsense oligonucleotides (Figure 2, C and D). Inhibition of miR-122 was associated with reduced CXCL2 but not CXCL1 expression (Figure 2, E and F) and the abolishment of RV-induced airway hyperreactivity (AHR) (Figure 2G). Interestingly, a reduced inflammatory response in the lung was associated with increased RV replication (Figure 2H) and innate IFN production in the lower airways (Figure 2, I and J).

RV infection is the most common cause for asthma attacks in childhood (3). In order to model a RV-induced asthma exacerbation, we challenged adult mice repeatedly with house dust mite allergen to induce allergic airway disease and then superimposed a RV infection (13). Similar to results found in non-allergic mice, miR-122 inhibition limited cell influx of neutrophils into the bronchoalveolar space, which was associated with reduced CXCL2 expression, abolishment of AHR, and increased RV replication and innate IFN production (Figure 3). These results demonstrate that RV-induced miR-122 promotes an influx of neutrophils into the lung along with AHR; together, these are associated with reduced RV replication and innate IFN expression in the presence and in the absence of allergic airway disease.

Suppressor of cytokine signaling 1 (SOCS1) is an *in silico*- and *in vitro*-validated target of miR-122 (16); SOCS1 operates as a ubiquitin ligase that causes the polyubiquitination and proteasomal degradation of nuclear p65, which terminates the expression of NF- κ B-inducible genes (17) and the suppression of RV-induced innate IFN production (18). The role of SOCS1 in RV infection renders it the most plausible *in vivo* target of miR-122 to mediate its actions on a posttranslational level. This hypothesis was supported by increased SOCS1 and reduced p65 protein levels in lungs of RV-infected mice treated with miR-122 antagomirs as compared with those treated with a scrambled oligonucleotide (Figure 4, A and B). In order to demonstrate unequivocally the mechanistic relevance of miR-122-SOCS1 target interaction *in vivo* for the expression of RV-induced lung disease, we treated mice with miR-122 antagomirs (or scrambled oligonucleotides) to increase the transcript levels of the miR-122 target SOCS1. Concurrent with this approach, we also silenced SOCS1 expression with inhibitory siRNA and compared the effects to treatment with a




Figure 4. Modulation of rhinovirus-induced lung disease by SOCS1 and miR-122 inhibition in adult mice. Naive BALB/c mice were treated with antagonists targeting miR-122 (A.122) or scrambled control (SCR). RV infection reduced levels of SOCS1 in the lungs, which was reversed by miR-122 inhibition (A) ($n = 3-5$ mice per group). The NF- κ B subunit p65 was upregulated by RV, and this upregulation was reversed by miR-122 inhibition (B) ($n = 3-5$ mice per group). In separate experiments, mice also received siRNA-targeting SOCS1 or a nonsense sequence siRNA as control (NON) along with A.122 or SCR before being infected with RV (C). The effects of miR-122 inhibition on neutrophil influx into the bronchoalveolar space (D), AHR (E), CXCL2 (F), and RV replication (G) were all neutralized by inhibition of SOCS1 ($n = 6-8$ mice per group). $*P \leq 0.05$, calculated using 1-way ANOVA with multiple comparisons correcting the false discovery rate 2-stage step-up method of Benjamini, Krieger, and Yekutieli, except for C-G, where 2-tailed t test was used to determine the effects of SOCS1 inhibition in A.122-treated mice. UV-RV, UV-inactivated RV. Data are shown as the mean \pm SEM.

scrambled nonsense siRNA (Figure 4C). Importantly, the effects of miR-122 inhibition on neutrophil influx into the bronchoalveolar space (Figure 4D), AHR (Figure 4E), CXCL2 expression (Figure 4F) and RV replication (Figure 4G) were all reversed by inhibition of SOCS1. Thus, miR-122 mediates its proinflammatory and antiviral effects in RV-induced lung disease at a posttranslational level via reduced SOCS1 in vivo.

Lower airway specimens in acute RV infection are difficult to obtain in nonventilated patients. We therefore quantified miR-122 expression in nasopharyngeal aspirates (NPAs) in a tertiary outcome analysis of NPA samples collected from 87 hospitalized infants with moderately severe bronchiolitis from a cohort of 202 infants who participated in a controlled trial in which they were randomized to either low- or high-flow oxygen supplementation therapy (1). There was no difference in baseline characteristics between the original cohort and the 2 subgroups of infants from whom NPA supernatant or cell pellets were available for miR-122 expression profiling, with 52 of 87 individuals being conserved across both groups (Supplemental Table 1; supplemental material available online with this article; <https://doi.org/10.1172/jci.insight.127933DS1>). In the trial, the primary outcome was time on oxygen supplementation therapy, and secondary outcomes included treatment failure requiring escalation of care, such as transfer to an intensive care unit. Notably, infants with high miR-122 expression in NPA supernatants, defined as miR-122 expression above the median of the cohort, were on oxygen therapy for a significantly longer time, which was the primary outcome of the trial in which this study was nested (Figure 5, A and B). Furthermore, a statistical trend toward more infants with high miR-122 expression failing their allocated treatment compared with infants with low miR-122 expression (Figure 5C) was observed. Conversely, those children who failed their treatment also showed a trend toward higher miR-122 expression in their NPAs (Figure 5D). Importantly, miR-21 and miR-423, used as controls, were not associated with any of these outcomes (Figure 5, E-L). In addition, statistically




Figure 5. miRNA 122 in nasopharyngeal aspirates from infants admitted to the hospital with moderately severe bronchiolitis. Infants with high miR-122 expression spent more hours on oxygen during their admission (A and B) and failed treatment more often (C). Infants who failed treatment trended toward increased detectable levels of miR-122 expression (D). Infants with higher levels of control miRNAs miR-21 and miR-423 had no difference in time on oxygen (E, F, I, and J, respectively) and no differences in the rate of treatment failure (G and K). Those that failed treatment had no difference in the expression of either miR-21 (H) or miR-423 (L) ($n = 87$). * $P \leq 0.05$, calculated using Mann-Whitney test, except for B, F, and J, where Gehan-Breslow-Wilcoxon test was used to compare survival curves.

significant associations were observed between miR-122 expression and clinical outcomes in the sub-cohort with NPA cell pellets available (Supplemental Figure 1). These associations were seen across the cohort as a whole, with approximately one-half of the infants positive for RV and the other half positive for respiratory syncytial virus. Thus, miR-122 expression is associated with clinically important outcomes in infants admitted to the hospital with moderately severe bronchiolitis due to RV or respiratory syncytial virus infection. Future studies are required to elucidate the potential of monitoring miR-122 expression as a predictive biomarker for disease severity.

Discussion

miR-122 was initially thought to be a tissue-specific miRNA, representing 70% of the total miRNA population in the liver (19). In the liver, hepatitis C virus (HCV) may exploit miR-122 for viral replication, whereby miR-122 binds to the 5'-noncoding region of viral genomic RNA to promote viral stability and translation of viral proteins (20, 21). Our studies show an unexpected role of miR-122 in the lung and indicate its interaction with the host-derived antiviral response to promote neutrophilic inflammation in a SOCS1-dependent manner. Higher numbers of neutrophils in the airways are related to virus load in the lung, clinical severity of infection, and AHR in acute experimental RV infection of healthy individuals and subjects with asthma (22). Paradoxically, neutrophils may also play an important role in innate immune responses to clear virus (23). This may explain higher RV replication upon miR-122 inhibition at 24 hours of infection, which was not evident at later time points (Figure 2H and Figure 3B and data not shown). While inhibition of miR-122 reduced neutrophil influx, the expression of the chemoattractant CXCL2 but not CXCL1 was reduced. This complex regulatory interplay between CXCL1 and CXCL2 in neutrophilic chemotaxis, and the apparent paradox between protective and pathologic effects of neutrophils, requires further studies. Those may include investigations of the therapeutic potential of targeting neutrophil extracellular traps, which contribute to the severity of RV-induced asthma exacerbations (24, 25). The clinical relevance of miR-122 in the modulation of virus-induced respiratory tract infections was supported by an association between higher miR-122 expression in NPA and longer time on oxygen treatment and trends with higher rates of treatment failure in infants with bronchiolitis. We, therefore, propose that targeting of miR-122 may be of therapeutic benefit in RV-induced lung disease. As bronchiolitis in early life is a strong risk factor for the development of asthma (26), disease-modifying treatments may have the potential to ameliorate asthma in susceptible children. These hypotheses are testable, as anti-miR-122 oligonucleotides have been trialed in phase I and II clinical studies involving subjects with HCV infection. One administration of a hepatocyte-targeted N-acetylgalactosamine-conjugated anti-miR-122 oligonucleotide was well tolerated and resulted in substantial HCV viral load reduction (27). The use of Miravirsin, a locked nucleic acid-modified DNA phosphorothioate antisense oligonucleotide for miR-122, showed prolonged dose-dependent reductions in HCV RNA levels (28). All together, we have shown a role of miR-122 in promoting RV-induced lung disease that has the potential to be therapeutically and diagnostically exploitable in the future.

Methods

Additional information can be found in Supplemental Methods.

Study approval. All mouse experiments were approved by the Animal Care and Ethics Committee of the University of Newcastle. All patient samples were collected after written informed consent from the parent. The study was approved by the Human Research Ethics Committees of the Hunter New England Local Health District, Newcastle, New South Wales, Australia, and the University of Newcastle.

Author contributions

AMC and LAS designed and performed the experiments, analyzed data, and drafted the manuscript. EK coordinated the clinical trial and provided samples. APDS, MM, MY, and THN assisted with assays and technical expertise. MRE, RPW, NWB, and SLJ provided the RV for the animal models and expertise. PSF supervised experiments and interpreted data. JM coordinated, designed and supervised experiments and the clinical trial; interpreted clinical and experimental data; and drafted manuscript versions. All authors reviewed and edited the manuscript.

Acknowledgments

We would like to thank J. Girkin, L. Hatchwell, J. Grehan, M. Lowe, E. Esteves, and K. Nichol for their assistance and the High-flow Warm Humidified Oxygen RCT team for assisting with the clinical trial. We thank Nathan Moon for providing clinical samples. Immortalized basal cells were provided by Peter Wark, Newcastle, New South Wales, Australia. This work was supported by the National Health and Medical Research Council (1011153 and 1060074 to JM) and the Hunter Medical Research Institute (to AMC and JM). SLJ is the Asthma UK Clinical Chair (grant CH11SJ) and a National Institute of Health Research (NIHR) Emeritus Senior Investigator; SLJ is funded in part by European Research Council Advanced Grant 788575. This research was supported by the NIHR Imperial Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.

Address correspondence to: Joerg Mattes, Priority Research Centre GrowUpWell, Hunter Medical Research Institute, Lookout Road, New Lambton, New South Wales 2305, Australia. Phone: 02.40420209; Email: Joerg.Mattes@newcastle.edu.au.

1. Kepreotes E, et al. High-flow warm humidified oxygen versus standard low-flow nasal cannula oxygen for moderate bronchiolitis (HFWHO RCT): an open, phase 4, randomised controlled trial. *Lancet*. 2017;389(10072):930–939.
2. Cox DW, et al. Human rhinovirus species C infection in young children with acute wheeze is associated with increased acute respiratory hospital admissions. *Am J Respir Crit Care Med*. 2013;188(11):1358–1364.
3. Johnston SL, et al. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. *BMJ*. 1995;310(6989):1225–1229.
4. Venarske DL, et al. The relationship of rhinovirus-associated asthma hospitalizations with inhaled corticosteroids and smoking. *J Infect Dis*. 2006;193(11):1536–1543.
5. Maffey AF, et al. Viruses and atypical bacteria associated with asthma exacerbations in hospitalized children. *Pediatr Pulmonol*. 2010;45(6):619–625.
6. Lai EC. Micro RNAs are complementary to 3' UTR sequence motifs that mediate negative post-transcriptional regulation. *Nat Genet*. 2002;30(4):363–364.
7. Krutzfeldt J, et al. Specificity, duplex degradation and subcellular localization of antagomirs. *Nucleic Acids Res*. 2007;35(9):2885–2892.
8. Podsiad A, et al. Micro RNA 155 regulates host immune response to post viral bacterial pneumonia via IL-23/Th17 pathway. *Am J Physiol Lung Cell Mol Physiol*. 2016;310(5):L465–475.
9. Hou J, et al. MicroRNA-146a feedback inhibits RIG-I-dependent type I IFN production in macrophages by targeting TRAF6, IRAK1, and IRAK2. *J Immunol*. 2009;183(3):2150–2158.
10. Mattes J, et al. Antagonism of microRNA-126 suppresses the effector function of TH2 cells and the development of allergic airways disease. *Proc Natl Acad Sci U S A*. 2009;106(44):18704–18709.
11. Collison A, et al. Inhibition of house dust mite-induced allergic airways disease by antagonism of microRNA-145 is comparable to glucocorticoid treatment. *J Allergy Clin Immunol*. 2011;128(1):160–167.
12. Gutierrez MJ, et al. Airway secretory microRNAome changes during rhinovirus infection in early childhood. *PLoS One*. 2016;11(9):e0162244.
13. Collison A, et al. The E3 ubiquitin ligase midline 1 promotes allergen and rhinovirus-induced asthma by inhibiting protein phosphatase 2A activity. *Nat Med*. 2013;19(2):232–237.
14. Choudhary S, et al. Respiratory syncytial virus influences NF-kappaB-dependent gene expression through a novel pathway involving MAP3K14/NIK expression and nuclear complex formation with NF-kappaB2. *J Virol*. 2005;79(14):8948–8959.
15. Yoboua F, et al. Respiratory syncytial virus-mediated NF-kappa B p65 phosphorylation at serine 536 is dependent on RIG-I, TRAF6, and IKK beta. *J Virol*. 2010;84(14):7267–7277.
16. Li A, et al. MiR-122 modulates type I interferon expression through blocking suppressor of cytokine signaling 1. *Int J Biochem Cell Biol*. 2013;45(4):858–865.
17. Strebovsky J, et al. Suppressor of cytokine signaling 1 (SOCS1) limits NFkappaB signaling by decreasing p65 stability within the cell nucleus. *FASEB J*. 2011;25(3):863–874.
18. Gielen V, et al. Increased nuclear suppressor of cytokine signaling 1 in asthmatic bronchial epithelium suppresses rhinovirus induction of innate interferons. *J Allergy Clin Immunol*. 2015;136(1):177–188.
19. Chang J, et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. *RNA Biol*. 2004;1(2):106–113.
20. Jopling CL, et al. Positive and negative modulation of viral and cellular mRNAs by liver-specific microRNA miR-122. *Cold Spring Harb Symp Quant Biol*. 2006;71:369–376.
21. Jopling CL, et al. Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. *Science*. 2005;309(5740):1577–1581.
22. Zhu J, et al. Airway inflammation and illness severity in response to experimental rhinovirus infection in asthma. *Chest*. 2014;145(6):1219–1229.
23. Smith JA. Neutrophils, host defense, and inflammation: a double-edged sword. *J Leukoc Biol*. 1994;56(6):672–686.
24. Krishnamoorthy N, et al. Neutrophil cytoplasmic granules induce T_H17 differentiation and skew inflammation toward neutrophilia in severe asthma. *Sci Immunol*. 2018;3(26):ea04747.
25. Toussaint M, et al. Host DNA released by NETosis promotes rhinovirus-induced type-2 allergic asthma exacerbation. *Nat Med*. 2017;23(6):681–691.
26. Caliskan M, et al. Rhinovirus wheezing illness and genetic risk of childhood-onset asthma. *N Engl J Med*. 2013;368(15):1398–1407.
27. van der Ree MH, et al. Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial. *Lancet*. 2017;389(10070):709–717.
28. Janssen HL, et al. Treatment of HCV infection by targeting microRNA. *N Engl J Med*. 2013;368(18):1685–1694.